Cardiovascular Assessment and Treatment During COPD Exacerbation to Improve Diagnosis and Outcomes

Condition(s) studied

Investigational drug(s) / intervention(s)

Cardiologist evaluation: The cardiology consultation will include the following: a structured interview (see Appendix A), physical examination, review of laboratory tests including HbA1c, lipid profile, BNP, ECG, and POCUS (point-of-care ultrasound) to assess heart contraction and valve function.

Pulmonologist evaluation: optimize basic treatment, and recommend continued follow-up as needed.

Study summary

This is a research study involving patients hospitalized for COPD flare-ups. Patients will be assigned using a non-randomized, sequential allocation strategy (a control cohort followed by an intervention cohort) to two groups: one group will only see a pulmonologist (lung doctor), and the other group will also be seen by a cardiologist (heart doctor) during their hospital stay. Both groups will fill out a questionnaire, and the pulmonologist will review their lung disease, adjust their treatment, and recommend follow-up care. The cardiologist will also assess the second group for heart diseases (like high cholesterol, diabetes, heart disease, high blood pressure, or heart failure) and start or adjust heart treatment if needed. Both groups will be followed up by phone 1, 3, 6 and 12 months later to check for changes in treatment, new heart problems, COPD flare-ups, or death.

Eligibility

Primary outcome measure(s)

• Cardiovascular-related treatment change in 6 months — From enrollment to 6 months follow-up call
  New pharmacological treatment or intervention (e.g., angiography, surgery) for cardiovascular disease, including diabetes, hypertension, dyslipidemia, ischemic heart disease, stroke, valvular disease, or heart failure compared to at inclusion.

Trial sites (1)

More Tel-Aviv Sourasky Medical Center trials in Israel

Other trials for the same condition